Delaware
|
001-32325
|
13-3894575
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
File
Number)
|
(IRS
Employer Identification
No.)
|
|
420
Lexington Avenue, Suite 1609
|
|||
New
York, New York
10170
|
|||
(Address
of principal executive offices)
|
o
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
CALLISTO PHARMACEUTICALS, INC. | ||
|
|
|
By: | /s/ Gary S. Jacob | |
|
||
Gary
S. Jacob, Ph.D.
Chief
Executive Officer
|